Our present study used an ssRNA-sh-Pim-3 dual-function vector to treat melanoma and showed that this therapeutic strategy can subvert tumor-induced immunosuppression by inducing activation of both NK and CD8+ T cells and reducing the percentages of Tregs and MDSCs in the tumor microenvironment. The gene discussed is CD8A; the disease is melanoma.